title: Protective effects of telmisartan on ischemia/reperfusion injury of rat ovary: biochemical and histopathologic evaluation.
abstract: OBJECTIVE
  To evaluate the effects of telmisartan as an antioxidant and for its tissue protective properties and to study the biochemical and histopathologic changes in experimental ischemia and ischemia/reperfusion injuries in rat ovaries.
  
  
  METHODS
  Experimental study.
  
  
  METHODS
  Experimental surgery laboratory in a university department.
  
  
  METHODS
  Forty-eight female adult rats.
  
  
  METHODS
  I: sham operation; II: bilateral ovarian ischemia; III: 3 h ischemia + 3 h reperfusion. IV and V: Rats were administered 10 and 20 mg/kg doses of telmisartan, respectively, before 0.5 h of ischemia, and then ovarian ischemia was applied; after 3 h of ischemia, the ovaries were removed. VI and VII: 3 h ovarian ischemia was applied; 2.5 h after the induction of ischemia, rats were administered the same doses of telmisartan; at the end of 3 h of ischemia, the ovaries were removed and a 3 h reperfusion followed.
  
  
  METHODS
  Superoxide dismutase, inducible nitric oxide synthase, and myeloperoxidase activity in rat ovarian tissue; and histopathologic changes in the ovarian tissue of the rats.
  
  
  RESULTS
  Ischemia and ischemia-reperfusion increased the inducible nitric oxide synthase and myeloperoxidase activity while decreasing the super oxide dismutase activity significantly in comparison with the sham group. Before ischemia and ischemia/reperfusion, telmisartan reversed the trend in inducible nitric oxide synthase activities and the level of myeloperoxidase.
  
  
  CONCLUSIONS
  telmisartan is effective in reversing tissue damage induced by ischemia/reperfusion in ovaries.
authors.affiliation: Department of Obstetrics and Gynecology, Ataturk University School of Medicine, Terminal cad no. 14/2, 25200 Erzurum, Turkey. ykumtepe@hotmail.com
authors.forename: Yakup
authors.initials: Y
authors.lastname: Kumtepe
authors.forename: Fehmi
authors.initials: F
authors.lastname: Odabasoglu
authors.forename: Mehmet
authors.initials: M
authors.lastname: Karaca
authors.forename: Beyzagul
authors.initials: B
authors.lastname: Polat
authors.forename: Mesut Bünyamin
authors.initials: MB
authors.lastname: Halici
authors.forename: Osman Nuri
authors.initials: ON
authors.lastname: Keles
authors.forename: Zuhal
authors.initials: Z
authors.lastname: Altunkaynak
authors.forename: Fatma
authors.initials: F
authors.lastname: Gocer
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000378:metabolism / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010053:Ovary / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology / Q000517:prevention & control*; D013482:Superoxide Dismutase / Q000378:metabolism; D000077333:Telmisartan
chemical_list: D000975:Antioxidants; D001562:Benzimidazoles; D001565:Benzoates; D009195:Peroxidase; D052247:Nitric Oxide Synthase Type II; D013482:Superoxide Dismutase; D000077333:Telmisartan